Johnson & Johnson: An effective vaccine against delta variation

Johnson & Johnson: An effective vaccine against delta variation

(ats) The U.S. pharmaceutical team neutralized the delta variation of antibodies and their immune system cells, according to a study of a small number of eight people who were vaccinated by it.

A second study involving 20 vaccinated patients from Beth Israel Medical Center in Boston found similar results.

Data from these studies have been sent to the biroxive “pre-publication” site, where scientists can submit their work before publishing it in a scientific journal.

“We hope our vaccine provides long-term protection against Covid 19 and helps neutralize delta diversity,” said Paul Stoffels, science director at Johnson & Johnson, quoting a statement released Thursday evening.

“Data from more than eight months of research so far have shown that a single-dose vaccine” developed by the laboratory reduces a strong neutralizing antibody response, which does not diminish, and we notice even an improvement over time, “said research head Matthew Mummen. And development at Johnson & Johnson.

The World Health Organization on Thursday warned of a new wave of infections posed by delta variation in Europe, as the number of cases increases at a “dangerous rate” in Africa as it embarks on its health journey in hopes of renewing tourism.

Not out of Asia: Bangladesh has been under control since Thursday and as pollution continues to rise sharply, restrictions will be announced in Indonesia on Saturday.

See also  The need for emergency assistance packages is greater than calculated

You May Also Like

About the Author: Will Smith

"Social mediaholic. Tv fanatic. Gamer. Professional explorer. Amateur music junkie."

Leave a Reply

Your email address will not be published.